Notable Price Action: Can Chemours Co’s Tomorrow be Different? The Stock Just Broke Its High

Notable Price Action: Can Chemours Co's Tomorrow be Different? The Stock Just Broke Its High

The stock of Chemours Co (NYSE:CC) reached all time high today, Nov, 15 and still has $35.10 target or 65.00% above today’s $21.27 share price. This indicates more upside for the $3.94 billion company. This technical setup was reported by Barchart.com. If the $35.10 PT is reached, the company will be worth $2.56B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 358,069 shares traded hands. Chemours Co (NYSE:CC) has risen 175.59% since April 13, 2016 and is uptrending. It has outperformed by 171.66% the S&P500.

Chemours Co (NYSE:CC) Ratings Coverage

Out of 8 analysts covering Chemours (NYSE:CC), 3 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 38% are positive. $19 is the highest target while $5.25 is the lowest. The $11.38 average target is -46.50% below today’s ($21.27) stock price. Chemours has been the topic of 16 analyst reports since July 27, 2015 according to StockzIntelligence Inc. On Friday, August 7 the stock rating was upgraded by JP Morgan to “Underweight”. The firm has “Hold” rating by Argus Research given on Friday, September 18. Citigroup maintained the shares of CC in a report on Monday, April 18 with “Neutral” rating. The stock of Chemours Co (NYSE:CC) earned “Neutral” rating by JP Morgan on Friday, August 7. The stock has “Neutral” rating given by Susquehanna on Monday, July 27. Citigroup initiated the shares of CC in a report on Friday, August 14 with “Neutral” rating. The stock of Chemours Co (NYSE:CC) has “Buy” rating given on Wednesday, August 10 by Argus Research. The firm has “Sell” rating given on Tuesday, August 18 by UBS. The company was upgraded on Monday, March 14 by Goldman Sachs. The company was maintained on Thursday, September 1 by Jefferies.

According to Zacks Investment Research, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington.”

More important recent Chemours Co (NYSE:CC) news were published by: Fool.com which released: “Chemours Co Surges After New Jury Verdict” on July 08, 2016, also Investorplace.com published article titled: “Trade of the Day: Chemours Co (NYSE:CC)”, Valuewalk.com published: “Chemours Co (CC) “Most Morally And Financially Bankrupt Company” Ever: Citron …” on June 02, 2016. More interesting news about Chemours Co (NYSE:CC) was released by: Valuewalk.com and their article: “Chemours Co (CC) Starts To Rally After Tanking On Wednesday” with publication date: July 07, 2016.

CC Company Profile

The Chemours Company, incorporated on February 18, 2014, is a well-known provider of performance chemicals. The Firm operates through three divisions: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Company’s Titanium Technologies segment produces titanium dioxide (TiO2). The Company’s Fluoroproducts segment provides fluoroproducts, such as refrigerants and industrial fluoropolymer resins. The Company’s Chemical Solutions segment provides industrial and specialty chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries. The Firm operates approximately 30 production facilities located in over 10 countries and serves a range of end markets in over 130 countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment